Ali Pooria
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ali Pooria has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Afsoun Pourya
Student of Research committee, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication- Alireza Gheini
Department of Cardiology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
1 shared publication Azadeh Razian
Student of Research Committee Lorestan University of Medical Sciences Khorramabad Iran
1 shared publicationBabak Hadian
Department of Internal Medicine, School of Medicine Lorestan University of Medical Sciences Khorramabad Iran
1 shared publication- Morteza Azadbakht
Department of Surgery, School of Medicine Lorestan University of Medical Sciences Khorramabad Iran
1 shared publication
Latest Publications
- Open Access
- 9 May 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (5) , e2057
Comparison of the effect of heparin, reteplase, and taurolock in the prevention of thrombosis in hemodialysis catheters
Background and Aim: One of the complications of using catheters is the occurrence of thrombosis, which can be dangerous for patients. The main objective of this study is to compare the effect of heparin, reteplase, and taurolock in the prevention of thrombosis in hemodialysis catheters.Methods: The present study is a clinical trial, in which the effect of three drugs, heparin, reteplase, and taurolock, in the prevention of thrombosis in hemodialysis catheters, has been investigated. The research units were studied in two intervention and control groups. The stratified random allocation method was used to assign patients to five groups (control, Heparin 50, Heparin 1000, reteplase, and taurolock), with strata based on the patient's age (20–70 years), gender, and duration of dialysis. Within each stratum, patients were also assigned to groups using the randomized block permutation method and a random number table tool. To prevent bias, this study is triple‐blinded. This means that the patient, the thrombosis assessor, and the statistical analyst are unaware of the type of intervention received by the patient.Results: Gender (p < 0.999), age distribution (p = 0.774), and duration of dialysis (p = 0.875) showed no statistically significant relationship with thrombosis. However, significant differences were observed among the five groups regarding thrombosis incidence. The relative risk of thrombosis in the Heparin 50, Heparin 1000, reteplase, and taurolock groups compared to the control group was 92.5%, 92.2%, 98.2%, and 89% lower, respectively.Conclusion: Our study underscores the efficacy of heparin, reteplase, and taurolock in preventing thrombosis in hemodialysis catheters. While all three drugs demonstrated efficacy, the Heparin 50 group exhibited the highest relative risk reduction. These findings suggest that heparin, particularly at a low dose, should be considered a standard prophylactic treatment in hemodialysis patients.
- 9 May 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (5) , e2057
Open AccessComparison of the effect of heparin, reteplase, and taurolock in the prevention of thrombosis in hemodialysis catheters
Background and Aim: One of the complications of using catheters is the occurrence of thrombosis, which can be dangerous for patients. The main objective of this study is to compare the effect of heparin, reteplase, and taurolock in the prevention of thrombosis in hemodialysis catheters.Methods: The present study is a clinical trial, in which the effect of three drugs, heparin, reteplase, and taurolock, in the prevention of thrombosis in hemodialysis catheters, has been investigated. The research units were studied in two intervention and control groups. The stratified random allocation method was used to assign patients to five groups (control, Heparin 50, Heparin 1000, reteplase, and taurolock), with strata based on the patient's age (20–70 years), gender, and duration of dialysis. Within each stratum, patients were also assigned to groups using the randomized block permutation method and a random number table tool. To prevent bias, this study is triple‐blinded. This means that the patient, the thrombosis assessor, and the statistical analyst are unaware of the type of intervention received by the patient.Results: Gender (p < 0.999), age distribution (p = 0.774), and duration of dialysis (p = 0.875) showed no statistically significant relationship with thrombosis. However, significant differences were observed among the five groups regarding thrombosis incidence. The relative risk of thrombosis in the Heparin 50, Heparin 1000, reteplase, and taurolock groups compared to the control group was 92.5%, 92.2%, 98.2%, and 89% lower, respectively.Conclusion: Our study underscores the efficacy of heparin, reteplase, and taurolock in preventing thrombosis in hemodialysis catheters. While all three drugs demonstrated efficacy, the Heparin 50 group exhibited the highest relative risk reduction. These findings suggest that heparin, particularly at a low dose, should be considered a standard prophylactic treatment in hemodialysis patients.
- 4 June 2020
- Published by Taylor & Francis in Future Cardiology
- Vol. 16 (5) , 481-496
Postoperative Complications Associated With Coronary Artery Bypass Graft Surgery and Their Therapeutic Interventions
Coronary artery disease is one of the commonest surgery demanding cardiovascular diseases. Coronary artery bypass graft surgery is practiced all over the world for the treatment of coronary artery ... Graphical abstract
- 4 June 2020
- Published by Taylor & Francis in Future Cardiology
- Vol. 16 (5) , 481-496
Postoperative Complications Associated With Coronary Artery Bypass Graft Surgery and Their Therapeutic Interventions
Coronary artery disease is one of the commonest surgery demanding cardiovascular diseases. Coronary artery bypass graft surgery is practiced all over the world for the treatment of coronary artery ... Graphical abstract